CTXR
Citius Pharmaceuticals, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 24 Citius Pharmaceuticals entered into a securities purchase agreement…
- R Apr 24 Citius Pharmaceuticals is raising $5 million through a registered di…
- R May 15 Citius Pharmaceuticals reported Q2 fiscal 2026 revenue of $1.7M (vs…
- R May 22 Citius Pharmaceuticals filed an S-3 registration statement to regist…
- R Jun 3 The SEC declared effective Citius Pharmaceuticals' S-3 shelf registr…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 3 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.250 → −$0.410 over 90 days. 0 up, 1 down in 30 days.
- TrendDOWNTREND
17% below its 50-day average. New closing low $0.3710 on Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | DOUBLED | $74.3K |
| NORTHERN TRUST CORP | ADD | $37.9K |
| UBS Group AG | TRIM | $15.9K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | $7.1K |
| MORGAN STANLEY | NEAR_EXIT | $27.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $221.6K |
| UBS Group AG | TRIM | $49.5K |
| JANE STREET GROUP, LLC | ADD | $20.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Mar 2026Price is below the lowest target. Median implies +791%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Mar 11, 2026 | D. Boral Capital MAINTAIN | Buy |
| Dec 4, 2025 | D. Boral Capital MAINTAIN | Buy |
| Aug 13, 2025 | D. Boral Capital MAINTAIN | Buy |
| Jun 30, 2025 | D. Boral Capital MAINTAIN | Buy |
| Jun 10, 2025 | D. Boral Capital MAINTAIN | Buy |
| Jun 9, 2025 | D. Boral Capital MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.41 | -$0.41–-$0.41 | -64.0% | $2.9M |
| Next Q | -$0.38 | -$0.38–-$0.38 | — | $4.4M |
| Current FY | -$2.03 | -$2.03–-$2.03 | -8.6% | $10.1M |
| Next FY | -$1.44 | -$1.44–-$1.44 | -77.8% | $20.5M |
Short side
FINRA· Oct 15, 2026SecBot reports
8 filings · 1 bullish · 5 bearish · 2 neutral- NEUTRAL 8-KOct 26, 2026
Citius Oncology reported preliminary Q4 FY2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 360 units in Q3, and 950 vials ordered by prescribing centers. Revenue recognition occurs upon wholesaler fulfillment, so actual Q4 revenue will be reported in December 2026.
🔒 Fresh report (last 24h), subscribers only
- BULLISH 8-KAug 5, 2026
Citius Pharma's subsidiary Citius Oncology reported strong commercial momentum for its newly…
The 78% QoQ increase in ordering institutions and 31% vial order growth suggest the LYMPHIR launch is gaining tangible traction. Monitor the next quarterly filing (10-K for period ending September…
- BEARISH EFFECTJun 3, 2026
The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on…
The shelf effectiveness enables immediate warrant-share resales, likely pressuring CTXR's stock price given the ~20% overhang and distressed financials (going-concern, $4.6M cash). Monitor for…
- NEUTRAL 8-KJun 1, 2026
Citius Pharmaceuticals' subsidiary Citius Oncology presented Phase 1 data for LYMPHIR in…
The data are exploratory and do not alter the immediate commercial trajectory for LYMPHIR in CTCL. Monitor for a Phase 2 start and any partnership or financing developments. At $18M market cap…
All CTXR filing & press-release reports (8)
- 8-K reportOct 26, 2026
- 8-K reportAug 5, 2026
- EFFECT reportJun 3, 2026
- 8-K reportJun 1, 2026
- S-3 reportMay 22, 2026
- 8-K reportMay 15, 2026
- 8-K reportApr 24, 2026
- 424B5 reportApr 24, 2026